Capricor Therapeutics, Inc. (CAPR, Financial) experienced a notable stock price increase, rising by 5.40%. The stock is currently priced at $20.09 per share with a trading volume of 763,419 shares, reflecting a turnover rate of 1.68% and a price fluctuation amplitude of 6.80%.
Recent financial reports show Capricor Therapeutics recorded $2.26 million in revenue, with a net loss of $12.56 million, resulting in an earnings per share (EPS) of -$0.38. The company's gross profit was $1.90 million, and it holds a price-to-earnings (P/E) ratio of -19.57.
In terms of analyst ratings, all seven institutions covering the stock have given it a "buy" recommendation, with none suggesting a "hold" or "sell." This positive outlook is reflected in the biotechnology sector's overall growth of 0.80%.
Within the biotechnology industry, other stocks such as Neurosense Therapeutics Ltd, Protagenic Therapeutics Inc, and Rocket Pharmaceuticals Inc have also shown significant gains. Meanwhile, companies like Cyclerion Therapeutics, Inc., Outlook Therapeutics, Inc., and Tc Biopharm (Holdings) Plc demonstrated high turnover rates.
Capricor Therapeutics is a biotechnology firm focused on advancing cellular and exosome therapies, particularly for rare diseases. Its product lineup includes CAP-1002, an allogeneic heart-derived cell therapy currently in Phase 3 clinical development for Duchenne muscular dystrophy. The company leverages its proprietary StealthXTM platform to conduct preclinical research in vaccinology, delivering oligonucleotides, proteins, and small molecules for targeted disease treatment and prevention.
